This is a side-by-side look at compression vs medication for Restless Legs Syndrome in 2026. You will see what the trial measured. You will see what the 2024 American Academy of Sleep Medicine guideline changed. You will see what each option costs in side effects and money, and how to choose without arguing with your GP.
The short answer: compression won the only head-to-head trial
You came here for a verdict, not a literature review, so here is the verdict first.
The compression arm beat the medication arm 90 per cent to 63 per cent on the standard sleep-medicine measure of “are you actually better.” That measure is the Clinical Global Impression scale. The result comes from an eight-week randomised trial by Kuhn and colleagues, published in the Journal of the American Osteopathic Association in 2016. Thirty adults with moderate-to-severe primary Restless Legs Syndrome compared targeted foot compression against ropinirole. Compression came out 1.4 times more effective than the drug.
That is the only published head-to-head trial of compression vs medication for Restless Legs. It is small and short, and it is not the final word. But it is the strongest piece of comparative evidence in the field, and it lands on the side of compression. Most women in Australia have never been told this number, including by the GPs prescribing ropinirole every week.
Side-by-side: compression vs medication for Restless Legs
You want the dimensions that actually matter when you are choosing. Here they are, ranked by what women in this position usually ask first.
| What you care about | Targeted overnight compression | Dopamine agonists (ropinirole, Sifrol/pramipexole) |
|---|---|---|
| Symptom improvement in trial | 90 per cent (Kuhn et al. 2016) | 63 per cent (Kuhn et al. 2016) |
| 2024 AASM guideline status | Not addressed; non-pharmacologic options recognised as reasonable first steps | Conditional recommendation against routine ongoing use |
| Augmentation risk | None reported | Real, well-documented; symptoms can worsen over months to years |
| Common side effects | Mild pressure marks, occasional warmth | Nausea, daytime sleepiness, dizziness, impulse-control issues, rebound symptoms |
| Prescription needed | No | Yes |
| Time to first effect | First night for some, within two weeks for most | Hours to days, then often a long taper if it stops working |
| Ongoing cost (AU) | One pair, founders’ pricing on first run | Ongoing PBS or private script, plus GP visits |
| Drug interactions | None | Multiple, especially with antidepressants and antihistamines |
| Travel friendliness | Pack it, wear it | Pack it, plan timing, manage augmentation if doses get missed |
| Long-term outlook | No published worsening pattern | Augmentation rate rises with years of use |
The comparison is less close than the conventional GP conversation suggests. Medication still has a place and we will get to that. But on the dimensions women usually weight most heavily, does it work, will it stop working, will it make me feel worse, the table tilts toward compression.
Why the 2024 AASM guideline changed the medication conversation
If your GP is still leading with Sifrol or ropinirole, the guideline has moved underneath them. The current evidence does not back the old default.
The headline change came in September 2024, when the American Academy of Sleep Medicine (AASM) updated its clinical practice guideline for Restless Legs Syndrome. The AASM now suggests against the routine, ongoing use of pramipexole (sold as Sifrol in Australia) and ropinirole as standard treatment. Both were first-line for years. Both are now conditional-against, on the basis of augmentation risk, the gradual worsening of the very symptoms the drug was meant to settle. The guideline now prefers the alpha-2-delta ligand class (gabapentin enacarbil, gabapentin, pregabalin) when medication is warranted, and strongly recommends intravenous iron correction for adults with ferritin under 100 micrograms per litre.
The practical effect for the compression conversation is this. The drug your sister-in-law tried in 2019, the one her GP still prescribes, is no longer the recommended first call. The case for trying a drug-free option before reaching for the script is now backed by the peak sleep-medicine body in the field, not just the women’s-health forums.
What ropinirole and Sifrol actually do (and why some women want out)
You want to know what the medication is doing inside you before you decide to keep taking it or stop.
For most women, ropinirole and pramipexole (Sifrol) work quickly at the start. The legs go quiet. Sleep returns. The first six to twelve months can feel like a small miracle. Both drugs are dopamine agonists; they mimic the action of dopamine in the brain, the neurotransmitter that manages the urge-to-move signal driving Restless Legs symptoms.
The catch is augmentation. Over months to years, the brain adapts. Symptoms can start earlier in the day, spread to the arms, or become more intense at the same dose. The instinctive response (take more) usually makes augmentation worse. Stopping the drug becomes harder than starting it. This is why the 2024 AASM guideline now recommends against routine ongoing use. So many women in their late 40s and 50s describe the drug as “great until it wasn’t.” If you have searched for “ropinirole alternative” or “restless legs without medication,” you are part of a very large cohort.
Common side effects layered on top: nausea, daytime sleepiness, dizziness, vivid dreams, weight changes, and a small but real risk of impulse-control issues like gambling and compulsive shopping. None of this is rare, and none of it is something you have to put up with.
What targeted overnight compression actually does
You came here weighing your options, so here is the non-drug option in plain terms.
For most women in the trial, the result was a quieter night within the first fortnight and a meaningful drop in their Restless Legs Severity Score by week eight. The mechanism is targeted overnight compression: steady, low-pressure contact with a specific area of the foot that research shows responds to pressure. It is worn during sleep, on both feet, with no pump, no batteries, and no electrical stimulation. The pressure pattern is designed to settle the nervous-system signal that drives the urge to move before that signal builds.
For a partner-shared bed and a 5am alarm, the clinical wrap from the trial is not the form factor you want. Stillr is the wearable, sleep-friendly version of the same category. The patent-pending compression structure is built into a low-profile foot sleeve that ends just above the ankle bone, with the toes left free.
The honest case for medication, and the honest case for compression
You do not have to pick a side to read this article, but you do have to choose for yourself tonight. Both options have a case.
The honest case for medication: a short course of an alpha-2-delta ligand under specialist supervision can buy you space while you build the rest of the plan. This is the right call if your symptoms are severe, daily, and already disrupting work and relationships. The 2024 AASM guideline still recognises a role for medication; it has just moved the dopamine agonists down the list. Augmentation is a risk, not a guarantee.
The honest case for compression: if you would rather not be on a long-term Restless Legs prescription, the trial evidence is on your side. The side-effect profile is mild, the cost is one-off, and the option does not interact with anything else you are taking. The 2016 trial was small and short, and it deserves more replication. But it is the strongest comparative data in the field, and it points the same direction the lived-experience reports do. “Drug-free, on my own terms” is now a defensible clinical position, not a wellness aspiration.
Many women end up doing both for a window: keep the medication, trial compression, then taper with their GP as the legs settle. The two approaches do not interfere with each other.
What the research actually shows
Two pieces of evidence underpin the comparison.
Kuhn et al. (2016), Journal of the American Osteopathic Association. Eight-week randomised comparison of targeted foot compression against ropinirole in 30 adults with moderate-to-severe primary Restless Legs Syndrome. Compression produced 90 per cent improvement on the Clinical Global Impression scale; ropinirole produced 63 per cent. Compression was 1.4 times more effective than the prescription drug. Restless Legs Severity Score, sleep quality, and quality-of-life measures all favoured compression. No augmentation reported in the compression arm.
AASM clinical practice guideline (2024). Conditional recommendation against routine ongoing use of pramipexole and ropinirole for Restless Legs Syndrome, on the basis of augmentation risk. Preference for alpha-2-delta ligand medications (gabapentin enacarbil, gabapentin, pregabalin) when medication is warranted. Strong recommendation for intravenous ferric carboxymaltose in adults with serum ferritin below 100 micrograms per litre.
What the literature does not yet support: ordinary graduated medical compression socks (the chemist kind) as a Restless Legs treatment, magnesium powder alone as a cure, or the herbal “leg calm” products marketed online. None of those have trial data that compares to the Kuhn 2016 result.
What Stillr is, and isn’t
Stillr is a drug-free overnight compression sleeve, worn on both legs, designed to replicate the targeted-pressure mechanism behind the strongest non-drug evidence for Restless Legs Syndrome. It is unisex, sized for adult feet, and currently pre-launch in Australia. Every pair comes with a 30-Night Sleep Trial, full refund if it does not improve your sleep. Reserve your pair on the founders’ list at stillr.com.au, where current pricing and sizing are listed.
Stillr is not a medication, not a cure, and not medical advice on whether to continue, taper, or change a prescription. It is a wellness product, built around what the research suggests the body responds to, designed for women who want the legs quiet without staying on a long-term prescription.
If “drug-free, on my own terms” lands, join the founders’ list and we will hold a pair for you.